Table 5. The associations between the FEN1 rs4246215 polymorphism and clinical characteristics of BC patients.
| Variables | GG (%) | TT (%) | P * | OR (95%CI) | GT (%) | P * | OR (95%CI) | GT+TT (%) | P * | OR (95%CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Tumor size | ||||||||||
| <2 cm | 73 (38.8) | 20 (10.6) | 1.00 (reference) | 95 (50.5) | 1.00 (reference) | 115 (61.2) | 1.00 (reference) | |||
| ≥2 cm | 187 (50.3) | 31 (8.3) | 0.11 | 0.61 (0.32-1.13) | 154 (41.4) | 0.02 | 0.63 (0.44-0.92) | 185 (49.7) | 0.01 | 0.63 (0.44-0.90) |
| LN metastasis | ||||||||||
| Negative | 110 (46.6) | 23 (9.7) | 1.00 (reference) | 103 (43.6) | 1.00 (reference) | 126 (53.4) | 1.00 (reference) | |||
| Positive | 150 (46.3) | 28 (8.6) | 0.71 | 0.89 (0.49-1.63) | 146 (45.1) | 0.83 | 1.04 (0.73-1.48) | 174 (53.7) | 0.94 | 1.01 (0.72-1.42) |
| ER | ||||||||||
| Negative | 111 (44.9) | 26 (10.5) | 1.00 (reference) | 110 (44.5) | 1.00 (reference) | 136 (55.1) | 1.00 (reference) | |||
| Positive | 149 (47.6) | 25 (8.0) | 0.28 | 0.72 (0.39-1.31) | 139 (44.4) | 0.74 | 0.94 (0.66-1.34) | 164 (52.4) | 0.53 | 0.90 (0.64-1.26) |
| PR | ||||||||||
| Negative | 124 (48.6) | 25 (9.8) | 1.00 (reference) | 106 (41.6) | 1.00 (reference) | 131 (51.4) | 1.00 (reference) | |||
| Positive | 136 (44.6) | 26 (8.5) | 0.86 | 0.95 (0.52-1.73) | 143 (46.9) | 0.98 | 1.00 (0.70-1.41) | 169 (55.4) | 0.34 | 1.18 (0.84-1.64) |
| HER-2 | ||||||||||
| Negative | 185 (47.5) | 33 (8.5) | 1.00 (reference) | 171 (44.0) | 1.00 (reference) | 204 (52.4) | 1.00 (reference) | |||
| Positive | 75 (43.9) | 18 (10.5) | 0.36 | 1.35 (0.71-2.54) | 78 (45.6) | 0.54 | 1.13 (0.77-1.64) | 96 (56.1) | 0.42 | 1.16 (0.81-1.67) |
*
Two-sided χ2 test for the distributions of genotype frequencies.
LN: Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; HER-2: human epidermal growth factor receptor 2.